Andrew H Levin

US Patent:

20220343951, Oct 27, 2022

Filed:

Apr 21, 2022

Appl. No.:

17/726103

Inventors:

Andrew Levin - Warminster PA, US
Aaron Cohen - Jenkintown PA, US
Kyle Levin - West Chester PA, US

International Classification:

G11B 27/031
G06F 3/01
G06F 3/04815
G06T 19/00
G06T 13/40

Abstract:

Methods and apparatus for producing virtual concerts or other online collaborative events. One or more musicians or other presenters or contributors at disparate geolocations transmit continuums of audio and/or image data as well as synchronization data continuums. Digital processing may be used to superimpose musicians or other presenters or contributors onto a virtual background (such as a concert stage or other virtual environment). Audio and video feeds from multiple musicians or other presenters or contributors may be synchronized to give the appearance of each being on the same stage in a 2D, 3D or virtual reality (VR) environment. Multiple continuums of audio data may be transmitted at different speeds and quality in order to allow musicians, presenters or other contributors to remain synchronized while a remote production studio receives high quality data transmissions for generation of a combinative, immersive, multi-dimensional end user audio/visual experience.

US Patent:

20210315880, Oct 14, 2021

Filed:

Mar 19, 2021

Appl. No.:

17/207504

Inventors:

- Cambridge MA, US
David P. Hesson - Malvern PA, US
Andrew D. Levin - Newton MA, US

International Classification:

A61K 31/47
A61P 31/14
A61K 45/06
A61K 9/00

Abstract:

The invention provided methods of treating viral infections, such as COVID-19, by providing an agent that inhibits a nucleotide synthesis pathway. In certain methods, the agent is an inhibitor of dihydroorotate dehydrogenase, such as a brequinar. In certain methods, brequinar is provided to a subject according to a dosing regimen that tailors levels of the drug in the lungs to achieve optimal therapeutic benefit. The dosing regimen may include defined levels of brequinar administered to the subject or defined levels of brequinar attained the lungs of the subject. The invention also provides combination therapies in which an inhibitor of dihydroorotate dehydrogenase is provided together with a second therapeutic agent.

US Patent:

20210308117, Oct 7, 2021

Filed:

Mar 19, 2021

Appl. No.:

17/207511

Inventors:

- Cambridge MA, US
David P. Hesson - Malvern PA, US
Andrew D. Levin - Newton MA, US

International Classification:

A61K 31/47
A61K 45/06
A61P 31/14

Abstract:

The invention provided methods of treating viral infections, such as COVID-19, by providing an agent that inhibits a nucleotide synthesis pathway. In certain methods, the agent is an inhibitor of dihydroorotate dehydrogenase, such as a brequinar. In certain methods, brequinar is provided to a subject according to a dosing regimen that tailors levels of the drug in the lungs to achieve optimal therapeutic benefit. The dosing regimen may include defined levels of brequinar administered to the subject or defined levels of brequinar attained the lungs of the subject. The invention also provides combination therapies in which an inhibitor of dihydroorotate dehydrogenase is provided together with a second therapeutic agent.

US Patent:

20210290651, Sep 23, 2021

Filed:

Mar 19, 2021

Appl. No.:

17/207500

Inventors:

- Cambridge MA, US
David P. Hesson - Malvern PA, US
Andrew D. Levin - Newton MA, US

International Classification:

A61K 31/7056
A61K 31/47
A61K 31/513
A61K 31/675
A61K 31/4965
A61K 31/343
A61P 31/14

Abstract:

The invention provided methods of treating viral infections, such as COVID-19, by providing an agent that inhibits a nucleotide synthesis pathway. In certain methods, the agent is an inhibitor of dihydroorotate dehydrogenase, such as a brequinar. In certain methods, brequinar is provided to a subject according to a dosing regimen that tailors levels of the drug in the lungs to achieve optimal therapeutic benefit. The dosing regimen may include defined levels of brequinar administered to the subject or defined levels of brequinar attained the lungs of the subject. The invention also provides combination therapies in which an inhibitor of dihydroorotate dehydrogenase is provided together with a second therapeutic agent.